Related Experiment Video
Updated: Aug 2, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and
M E Brousseau1, M Bodzioch, E J Schaefer
1The Lipid Metabolism Laboratory, JM-USDA Human Nutrition Research Center on Aging at Tufts, Boston, MA, USA.
Insights
Common variants in the ATP-binding cassette transporter 1 (ABCA1) gene were studied for their effect on HDL cholesterol levels and coronary heart disease (CHD) risk. The G3456C variant showed an association with increased CHD risk in men with low HDL-C.
Area of Science:
- Genetics
- Cardiovascular Disease
- Lipid Metabolism
Background:
- Low HDL cholesterol is a common lipid abnormality linked to premature coronary heart disease (CHD).
- Mutations in the ATP-binding cassette transporter 1 (ABCA1) gene cause Tangier disease, a rare disorder associated with low HDL-C and increased CHD risk.
Purpose of the Study:
- To investigate whether common variants in the ABCA1 gene coding sequence influence plasma HDL-C levels and CHD risk in the general population.
Main Methods:
- Examined allele frequencies of three common ABCA1 variants (G596A, A2589G, G3456C) in men from the VA-HIT and Framingham Offspring Study (FOS).
- Assessed the association of these variants with plasma HDL-C concentrations and CHD endpoints.
Main Results:
- Allele frequencies for the variants differed between the VA-HIT and FOS populations (P<0.03).
- None of the ABCA1 variants were significantly associated with plasma HDL-C levels in either cohort.
- The G3456C variant was significantly associated with an increased risk of CHD endpoints in the VA-HIT cohort.
Conclusions:
- Common ABCA1 variants do not appear to significantly impact HDL-C levels in the general population.
- The ABCA1 G3456C variant may play a role in the predisposition to premature CHD observed in certain populations.
Abstract:
HDL cholesterol (HDL-C) deficiency is the most common lipid abnormality observed in patients with premature coronary heart disease (CHD). Recently, our laboratory and others demonstrated that mutations in the ATP-binding cassette transporter 1 (ABCA1) gene are responsible for Tangier disease, a rare genetic disorder characterized by severely diminished plasma HDL-C concentrations and a predisposition for CHD. To address the question of whether common variants within the coding sequence of ABCA1 may affect plasma HDL-C levels and CHD risk in the general population, we determined the frequencies of three common ABCA1 variants (G596A, A2589G and G3456C) in men participating in the Veterans Affairs Cooperative HDL Cholesterol Intervention Trial (VA-HIT), a study designed to examine the benefits of HDL raising in men having low HDL-C (< or =40 mg/dl) and established CHD, as well as in CHD-free men from the Framingham Offspring Study (FOS). Allele frequencies (%) in VA-HIT were 31, 16, and 4 for the G596A, A2589G, and G3456C variants, respectively, versus 27, 12, and 2 in FOS (P<0.03). None of the variants were significantly associated with plasma HDL-C concentrations in either population; however, in VA-HIT, the G3456C variant was associated with a significantly increased risk for CHD end points, suggesting a role for this variant in the premature CHD observed in this population.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease I: Introduction